Literature DB >> 26178866

Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.

Jae Ri Kim1, Jin-Young Jang1, Mee Joo Kang1, Taesung Park2, Seung Yeoun Lee3, Woohyun Jung1, Jihoon Chang1, Youngchan Shin1, Youngmin Han1, Sun-Whe Kim1.   

Abstract

BACKGROUND: Little is known about the prognostic significance of serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) concentrations for predicting malignancy in patients with intraductal papillary mucinous neoplasm (IPMN) of pancreas.
METHOD: The study cohort consisted of 367 patients with surgical biopsy proven IPMN at Seoul National University Hospital. Preoperative serum tumor markers were evaluated and compared with other clinical variables.
RESULTS: Malignant pathology (high grade dysplasia [HGD] and invasive IPMN) was identified in 117 (31.9%) patients. Elevated serum CA19-9 was more frequent in patients with malignant (34.2%, P < 0.001; invasive IPMN vs. HGD 47.9% vs. 11.4%, P < 0.001) and main duct type (40.0%, P = 0.003) IPMN. Multivariate analysis showed main pancreatic duct (MPD) >5 mm (P < 0.001), mural nodules (P < 0.001), and elevated serum CA19-9 (P < 0.001) were independent predictors of malignancy. The sensitivity, specificity and accuracy were 34.2%, 92.4%, and 73.8%, respectively, for elevated serum CA19-9; 63.3%, 78.0%, and 73.3%, for MPD >5 mm; and 59.0%, 86.4%, and 77.7%, for mural nodules.
CONCLUSION: Serum CA19-9 is significantly higher in patients with malignant IPMN, especially in patients with invasive and main duct type IPMN. The diagnostic power of serum CA19-9 in predicting malignancy is comparable to that of MPD >5 mm and mural nodules.
© 2015 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Carbohydrate antigen 19-9; Carcinoembryonic antigen; Intraductal papillary mucinous neoplasm; Malignancy predictor; Serum tumor marker

Mesh:

Substances:

Year:  2015        PMID: 26178866     DOI: 10.1002/jhbp.275

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  21 in total

Review 1.  [Cystic lesions of the pancreas : Differential diagnostics and treatment].

Authors:  J Rosendahl; P Michl
Journal:  Internist (Berl)       Date:  2019-03       Impact factor: 0.743

Review 2.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

Review 3.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 4.  Pancreatic Cystic Neoplasms: Different Types, Different Management, New Guidelines.

Authors:  Lianne Scholten; Nadine C M van Huijgevoort; Jeanin E van Hooft; Marc G Besselink; Marco Del Chiaro
Journal:  Visc Med       Date:  2018-06-08

5.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Strategic Considerations.

Authors:  Vicente Morales-Oyarvide; Zhi Ven Fong; Carlos Fernández-Del Castillo; Andrew L Warshaw
Journal:  Visc Med       Date:  2017-12-08

Review 6.  Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).

Authors:  Joseph Carmicheal; Asish Patel; Vipin Dalal; Pranita Atri; Amaninder S Dhaliwal; Uwe A Wittel; Mokenge P Malafa; Geoffrey Talmon; Benjamin J Swanson; Shailender Singh; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-30       Impact factor: 10.680

Review 7.  Ductal Dilatation of ≥5 mm in Intraductal Papillary Mucinous Neoplasm Should Trigger the Consideration for Pancreatectomy: A Meta-Analysis and Systematic Review of Resected Cases.

Authors:  Y H Andrew Wu; Atsushi Oba; Laurel Beaty; Kathryn L Colborn; Salvador Rodriguez Franco; Ben Harnke; Cheryl Meguid; Daniel Negrini; Roberto Valente; Steven Ahrendt; Richard D Schulick; Marco Del Chiaro
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

8.  European evidence-based guidelines on pancreatic cystic neoplasms.

Authors: 
Journal:  Gut       Date:  2018-03-24       Impact factor: 23.059

9.  The Ratio of C-Reactive Protein to Albumin Is an Independent Predictor of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Simone Serafini; Alberto Friziero; Cosimo Sperti; Lorenzo Vallese; Andrea Grego; Alfredo Piangerelli; Amanda Belluzzi; Lucia Moletta
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

Review 10.  Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pancreas.

Authors:  M Heckler; L Brieger; U Heger; T Pausch; C Tjaden; J Kaiser; M Tanaka; T Hackert; C W Michalski
Journal:  BJS Open       Date:  2018-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.